Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon therapy in malignant melanoma].

R Stadler1, C Garbe

  • 1Universitäts-Hautklinik, Klinikum Steglitz der Freien Universität Berlin.

Zeitschrift Fur Hautkrankheiten
|May 1, 1990
PubMed
Summary

Intralesional interferon shows higher efficacy in treating metastatic malignant melanoma than systemic application. Combination therapies are being explored to improve anti-tumor effects for better outcomes in dermato-oncology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Context:

  • Metastatic malignant melanoma presents a therapeutic challenge with limited systemic treatment efficacy.
  • Systemic interferon therapy for metastatic melanoma yields moderate response rates (approx. 11%).
  • Intralesional interferon demonstrates superior efficacy, achieving partial or complete regression in about 50% of tumors.

Purpose:

  • To evaluate the efficacy of different interferon application methods in metastatic malignant melanoma.
  • To explore combination therapies for enhancing anti-tumor effects of interferon.
  • To establish interferon-based therapeutic strategies in dermato-oncology.

Summary:

  • Systemic interferon administration in metastatic malignant melanoma shows limited effectiveness.
  • Intralesional administration of alpha- and beta-interferon results in significantly higher regression rates.
  • Combination studies, particularly with cytostatic drugs like dacarbazine and vindesine, show promise for enhanced anti-tumor activity.

Impact:

  • Intralesional interferon offers a more effective treatment option for melanoma metastases.
  • Combination therapies may improve therapeutic outcomes and establish new treatment standards.
  • Advances in dermato-oncology through improved interferon-based treatments for advanced melanoma.

Related Experiment Videos